Windtree Therapeutics Q3 2024 Earnings Report

Windtree Therapeutics EPS Results

• Actual EPS: -$211.50
• Consensus EPS: -$113.50
• Beat/Miss: Missed by -$98.00
• One Year Ago EPS: N/A

Windtree Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Windtree Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/26/2024
• Time: After Market Closes
• Conference Call Date: Tuesday, November 26, 2024
• Conference Call Time: 12:00AM ET

Windtree Therapeutics (NASDAQ:WINT) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular and pulmonary diseases. The company’s proprietary technology platforms include the KL4 surfactant formulation and the Aerosurf® (formerly AeriSeal®) polymer foam technology, both designed to address critical conditions such as neonatal respiratory distress syndrome (nRDS), acute respiratory distress syndrome (ARDS), and alveolar leaks associated with mechanical ventilation. By combining expertise in lipid science, pulmonary delivery, and critical care medicine, Windtree aims to fill unmet medical needs across a range of acute and life-threatening indications. Windtree’s product pipeline is anchored by its lead asset, KL4 surfactant, which is being evaluated for the prevention and treatment of nRDS in premature infants and for inflammatory lung diseases in adults. The Aerosurf polymer foam technology is engineered to seal alveolar air leaks and has potential applications in critical care settings, including ARDS and bronchopleural fistulas. In addition to these core programs, the company has initiated exploratory studies for potential treatments of pulmonary alveolar proteinosis and other rare lung disorders. Since its founding in 2006 and subsequent public listing on the NASDAQ under the ticker WINT, Windtree has maintained headquarters in Warrington, Pennsylvania, with research collaborations and clinical trial sites across North America, Europe, and Asia. The company leverages strategic partnerships with academic institutions, contract research organizations, and healthcare providers to support its global clinical development activities. Windtree’s management team brings together seasoned professionals from the pharmaceutical and biotechnology sectors. The company is led by Chief Executive Officer Robert Pangia, whose prior roles include senior leadership positions at specialty pharma and medical device companies. The board of directors comprises independent members with deep expertise in drug development, regulatory affairs, and commercial strategy. Together, Windtree’s leadership is committed to advancing its portfolio through late-stage clinical trials and toward potential regulatory approvals.